Insider Purchases: Inside the Buy

Tag: Stock Buyback

Coursera stock turnaround illustration featuring activist buying, Udemy synergies, AI learning and a $500 million share buyback.

Coursera Stock (COUR): An $11.4 Million Activist Bet on a Turnaround

Pale Fire Capital just invested another $11.4 million in Coursera. With the stock down roughly 92% from its peak, institutions holding nearly 96% of the float, $85 million-plus in targeted Udemy synergies and a $500 million buyback, COUR may be an asymmetric turnaround—or a remarkably well-funded value trap.

Read entire article

Tags: activist investor, Andrew Ng, buy or sell COUR stock, contrarian investing, COUR, COUR stock, COUR stock analysis, COUR stock price target, Coursera, Coursera earnings Q2 2026, Coursera stock, Coursera Udemy merger, edtech stocks, education technology, featured-hedge-funds, featured-insiders, FUNstock Index, FunStock Method, hub-hedge, hub-insiders, insider buying, insider purchases, institutional ownership, investment research, LearnVector, merger synergies, online education, Pale Fire Capital, Pale Fire Capital insider purchase, risks buying COUR stock, share buybacks, short interest, small-cap stocks, stock buyback, turnaround stocks, Udemy, Udemy merger synergies, value stocks, value stocks 2026, value trap, why buy COUR stock
Cinematic illustration of Boston Scientific as a futuristic medtech powerhouse, with glowing cardiovascular devices, a heart-shaped stock chart, doctors, investors, and a $2B buyback shield symbolizing healthcare innovation and a GARP stock opportunity.

🫀 Boston Scientific (BSX): A GARP Reset on a Medical Device Powerhouse

Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.

Read entire article

Tags: Boston Scientific, BostonScientific, BSX, BSX stock, buy or sell BSX, cardiovascular devices, CardiovascularTech, dividend growth stocks, FARAPULSE, featured-insiders, FUNanc1al, GARP, GARP investing, growth stocks, healthcare investing, healthcare stocks, hub-insiders, insider buying, InsiderBuying, medical device stocks, medical technology, MedicalDevices, MedTech, medtech stocks, NYSE BSX, risks buying BSX, ShareRepurchase, stock buyback, stock market analysis, value investing, ValueInvesting, WATCHMAN FLX, why buy BSX
Playful digital illustration of Roper Technologies’ CEO confidently climbing a brightly colored software-coded rope, surrounded by icons of cash flow arrows, rising charts, and a giant $3B buyback lifeline.

CEO Buys Shares of Roper Technologies: Knows the Ropes or On the Ropes?

A massive insider buy, a $3B share repurchase program, soaring cash flow, and institutions owning nearly the entire float. Is Roper Technologies signaling deep value—or just tugging on your curiosity rope?

Read entire article

Tags: Bears Walking a Tight Rope, BuyOrSell ROP stock, CEO Buys, CEO Conviction, CEO insider buying, CEO Insider Purchases, CEO Stock Purchase, CEOBuyIn, CEOConfidence, Compounders, Earnings, FUNanc1al, funanc1al edge, funanc1al humor, Insider Purchases, Institutional Ownership, Laurence Neil Hunn, low short interest, ROP stock, Rop Stock a Buy, Roper Technologies, Software Stocks, Stock Buyback, Why Invest in ROP